JPRN-jRCT2031220202尚未招募2 期
A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis - FRONTIER 2
akano Masayoshi0 个研究点目标入组 228 人开始时间: 2022年7月8日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 228
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Must have completed the Week 16 visit in Protocol 77242113PSO2001
- •- In the opinion of the investigator, may benefit from inclusion in this long term extension (LTE) study
- •- Must agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during the study
- •- Must agree to discontinue all topical therapies that could affect psoriasis or the psoriasis area severity index (PASI) or investigator's global assessment (IGA) evaluation, other than nonmedicated emollient and salicylic acid shampoos, prior to first administration of study intervention
- •- Agree not to receive a live virus or live bacterial vaccination during the study, or within 4 weeks after the last administration of study intervention
排除标准
- •- Was permanently discontinued from study intervention in Protocol 77242113PSO2001 for any reason
- •- Has received any biologic therapy or experimental therapy since completion of the originating study, 77242113PSO2001
- •- Has received any live virus or bacterial vaccination within 12 weeks before the first administration of study intervention
- •- Has received the bacille Calmette-Guerin (BCG) vaccine within 12 months of the first administration of study intervention
- •- Currently has hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or has other clinically active liver disease, or tests positive for HBsAg or anti-HCV
研究者
相似试验
进行中（未招募）
1 期
A Long-Term Extension Study of JNJ-77242113 in Participants with Moderate-to-Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858Plaque PsoriasisEUCTR2021-004320-16-DEJanssen-Cilag International NV240
进行中（未招募）
1 期
A Long-Term Extension Study of JNJ-77242113 in Participants with Moderate-to-Severe Plaque PsoriasisPlaque PsoriasisEUCTR2021-004320-16-PLJanssen-Cilag International NV240
已完成
2 期
A Long-Term Extension Study of JNJ-77242113 in Participants with Moderate-to-Severe Plaque PsoriasisSkin and Connective Tissue DiseasesPlaque psoriasisPsoriasis vulgarisISRCTN15135908Janssen (Belgium)227
未知
2 期
A long-term extension study of TAK-385 in the treatment of endometriosisEndometriosisJPRN-jRCT2080221549TAKEDA PHARMACEUTICAL COMPANY LTD.397
进行中（未招募）
1 期
ong-term safety and tolerability study of atacicept in patients with Systemic Lupus Erythematosus who completed protocol EMR-700461-023 (ADDRESS II)Systemic Lupus Erythematosus (SLE)MedDRA version: 17.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-002758-62-DEMerck KGaA213